2. Search Result
Search Result
Results for "

memory T-cells

" in MedChemExpress (MCE) Product Catalog:

18

Inhibitors & Agonists

3

Peptides

6

Inhibitory Antibodies

1

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-148029
    Dazostinag disodium

    TAK-676

    		 STING Cancer
    Dazostinag disodium (TAK-676) is an agonist of STING, triggering the activation of STING signaling pathway and type I interferons. Dazostinag disodium is also a modulator of immune system, resulting complete regressions and durable memory T-cell immunity. Dazostinag disodium promotes durable IFN-dependent antitumor immunity .
    Dazostinag disodium
  • HY-P991192
    BI-1808

    		TNF Receptor Cancer
    BI-1808 is a human IgG1 monoclonal antibody that targets TNFR2by blocking interaction of TNFR2 with ligand TNF-α, confers FcγR-dependent depletion of Treg and mediates expansion of intratumoral CD8 + T cells .
    BI-1808
  • HY-P99945
    Revdofilimab

    ABBV-368

    		 Orexin Receptor (OX Receptor) Inflammation/Immunology Cancer
    Revdofilimab (ABBV-368) is a human IgG1 agonist monoclonal antibody against OX40. Among them, OX40 is a member of the TNF receptor superfamily expressed on activated and memory T cell subsets and T regulatory cells .
    Revdofilimab
  • HY-108583
    Psora-4

    5-(4-Phenylbutoxy)psoralen

    		 Potassium Channel Inflammation/Immunology
    Psora-4 is a potent and selective inhibitor of Kv1.3 (voltage-gated potassium channels) with an EC50 of 3 nM . Psora-4 has immunosuppressive activity and inhibits proliferation of human and rat myelin-specific effector memory T cells in vitro .
    Psora-4
  • HY-161982
    JNU-0921

    		TNF Receptor Cancer
    JNU-0921 is a potent and orally active CD137 agonist. JNU-0921 increases the mRNA expression of IFN-γ and GZMB. JNU-0921 induces luciferase activity with an EC50 value of 64.07 nM.JNU-0921 enhances effector and memory function of cytotoxic CD8 + T cells (CTLs) and alleviates their exhaustion. JNU-0921 also skews polarization of helper T cells toward T helper 1 type and enhances their activity to boost CTL function. JNU-0921 shows anticancer activity .
    JNU-0921
  • HY-P99129
    Anti-Mouse CD8a Antibody (53-6.7)
    2 Publications Verification

    		 Transmembrane Glycoprotein Inflammation/Immunology
    Anti-Mouse CD8a Antibody (53-6.7) is an anti-mouse CD8a IgG2a antibody inhibitor derived from host Rat. Anti-Mouse CD8a Antibody (53-6.7) binds to CD8αβ stabilizes a conformation with a higher affinity for interaction with MHC class I. Anti-Mouse CD8a Antibody (53-6.7) induces the phosphorylation and activation of TCR proximal signaling pathway components Lck and ZAP70 in polyclonal memory T cells. Anti-Mouse CD8a Antibody (53-6.7) depletes CD8+ T cells and neutralizes cytokine in mice .
    Anti-Mouse CD8a Antibody (53-6.7)
  • HY-P991543
    BTI-322

    		CD2 Inflammation/Immunology Cancer
    BTI-322 is a rat monoclonal IgG2b directed against the CD2 antigen on T cells and NK cells. BTI-322 can block primary and memory alloantigen proliferative responses in vitro. BTI-322 recognizes over 90% of E-rosette-forming peripheral blood lymphocytes and T-cell leukemias. BTI-322 has immunosuppressive activity. BTI-322 effectively inhibits T cell responses in vitro to allogeneic cells. BTI-322 can be used as a T-cell deplting agent. BTI-322 can be studied in research for renal allograft rejection and steroid-refractory acute graft-versus-host disease .
    BTI-322
  • HY-125881
    ASP1126

    		LPL Receptor Inflammation/Immunology
    ASP1126 is a selective and orally active sphingosine-1-phosphate (S1P) agonist, with EC50 values of 7.12 nM, 517 nM for hS1P1 and hS1P3, respectively. ASP1126 decreases the number of peripheral lymphocytes, naive T cells, central memory T cells and effector memory T cells in the peripheral blood. ASP1126 has the potential to be applied in clinical transplantation with improved safety profile .
    ASP1126
  • HY-N9737
    (−)-Acutumine

    		Others Neurological Disease
    (−)-Acutumine is a tetracyclic chloroalkaloid that exhibits selective cytotoxicity to cultured human T cells and memory-enhancing properties in the Wistar rat model .
    (−)-Acutumine
  • HY-P10851
    HVEM(14-39)

    		Apoptosis Inflammation/Immunology Cancer
    HVEM(14-39) is a B- and T-lymphocyte attenuator (BTLA) peptide inhibitor. HVEM (14-39) can be combined with BTLA with a KD of 0.102 μM. HVEM(14-39) enhances the activation and proliferation of T cells by regulating the expression of BTLA and HVEM in T cells, and promotes the transformation of cells into effector memory T cells. HVEM(14-39) inhibits tumor cell proliferation and promotes late apoptosis. HVEM(14-39) has immunomodulatory effects and can be used in the study of cancer .
    HVEM(14-39)
  • HY-169480
    Lipid C2

    		Liposome Infection Cancer
    Lipid C2 is an ionizable cationic lipid that has been used in the formation of lipid nanoparticles (LNP) for mRNA delivery in vivo. LNPs containing Lipid C2 and encapsulating an mRNA reporter selectively accumulate in the liver and spleen but not the heart, lungs, or kidneys in mice. LNP containing Lipid C2 and encapsulating mRNA encoding the Epstein-Barr virus (EBV) protein latent membrane protein 2 (LMP-2), in combination with an anti-programmed cell death protein 1 (PD-1) antibody, decrease tumor volume and reverse T cell exhaustion, as well as increase the percentage of CD3 +CD8 + central and CD3 +CD8 + effector memory T cells and decrease the percentage of CD3 + T cells expressing Pd-1, in the spleen in a CT26 murine EBV-infected colon cancer model .
    Lipid C2
  • HY-P99687
    Latikafusp

    AMG 256

    		 PD-1/PD-L1 Cancer
    Latikafusp (AMG 256) is a bifunctional fusion protein comprising a PD-1-targeting antibody and IL-21 mutein designed to deliver IL-21 pathway stimulation to PD-1+ cells. Latikafusp is designed to prime and extend the activity of cytotoxic and memory T cells and induce anti-tumor immunity. Latikafusp has the potential for solid tumors research .Latikafusp may lead to the development of immunogenicity-mediated responses .
    Latikafusp
  • HY-P5917A
    Vm24-toxin TFA

    Vaejovis mexicanus peptide 24 TFA

    		 Potassium Channel Inflammation/Immunology Cancer
    Vm24-toxin (Vaejovis mexicanus peptide 24) TFA, a 36-residue peptide, is a potent and selective Kv1.3 blocker with a Kd of ~3 pM in lymphocytes. Vm24-toxin TFA shows >1500-fold affinity for Kv1.3 over other assayed potassium channels. Vm24-toxin TFA folds into a distorted cystine-stabilized α/β motif consisting of a single-turn α-helix and a three-stranded antiparallel β-sheet, stabilized by four disulfide bridges. Vm24-toxin TFA attenuates the CD4 + effector memory T cell response to T cell receptor (TCR) stimulation .
    Vm24-toxin TFA
  • HY-P5917
    Vm24-toxin

    Vaejovis mexicanus peptide 24

    		 Potassium Channel Inflammation/Immunology Cancer
    Vm24-toxin (Vaejovis mexicanus peptide 24), a 36-residue peptide, is a potent and selective Kv1.3 blocker with a Kd of ~3 pM in lymphocytes. Vm24-toxin shows >1500-fold affinity for Kv1.3 over other assayed potassium channels. Vm24-toxin folds into a distorted cystine-stabilized α/β motif consisting of a single-turn α-helix and a three-stranded antiparallel β-sheet, stabilized by four disulfide bridges. Vm24-toxin attenuates the CD4 + effector memory T cell response to T cell receptor (TCR) stimulation .
    Vm24-toxin
  • HY-144987
    RBN013209
    1 Publications Verification

    		 CD38 LAG-3 Tim3 PD-1/PD-L1 Inflammation/Immunology Cancer
    RBN013209 is an orally active small molecule inhibitor of CD38 with an IC50 of 0.01 to 0.1 μM for human CD38. RBN013209 prevents the conversion of extracellular NAD + to ADPR or cADPR in tumor cells and PBMCs. RBN013209 can be used in the study of tumor. In addition, RBN013209 enables CAR-T cells to maintain the naive state and central memory state, and decreases the expression of cell activation markers and exhaustion-related inhibitory receptors .
    RBN013209
  • HY-126675A
    AS2863619
    2 Publications Verification

    		 CDK STAT Inflammation/Immunology
    AS2863619 enables conversion of antigen-specific effector/memory T cells into Foxp3 + regulatory T (Treg) cells for the treatment of various immunological diseases. AS2863619 is a potent, orally active cyclin-dependent kinase 8 (CDK8) and CDK19 inhibitor with IC50s of 0.61 nM and 4.28 nM, respectively. STAT5 activation enhanced by AS2863619 inhibition of CDK8/19, which consequently activates the Foxp3 gene .
    AS2863619
  • HY-126675
    AS2863619 free base
    2 Publications Verification

    		 CDK STAT Inflammation/Immunology
    AS2863619 free base enables conversion of antigen-specific effector/memory T cells into Foxp3 + regulatory T (Treg) cells for the treatment of various immunological diseases. AS2863619 free base is a potent, orally active cyclin-dependent kinase 8 (CDK8) and CDK19 inhibitor with IC50s of 0.61 nM and 4.28 nM, respectively. STAT5 activation enhanced by AS2863619 free base inhibition of CDK8/19, which consequently activates the Foxp3 gene .
    AS2863619 free base
  • HY-P99119
    Anti-Mouse 4-1BB/CD137 Antibody (3H3)

    		TNF Receptor Bcl-2 Family Inflammation/Immunology Cancer
    Anti-Mouse 4-1BB/CD137 Antibody (3H3) is an anti-mouse 4-1BB/CD137 IgG2a monoclonal antibody. Anti-Mouse 4-1BB/CD137 Antibody (3H3) can effectively activate memory T cells and inhibit tumors by increasing Bcl-xL and granzyme B levels. Anti-Mouse 4-1BB/CD137 Antibody (3H3) can be used for research on cancer such as lymphoma and colon cancer .
    Anti-Mouse 4-1BB/CD137 Antibody (3H3)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: